Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting beta 2-agonists in chronic obstructive pulmonary disease.

Carol Llewellyn-Jones1

  • 1Department of Respiratory, West Wales General Hospital, Glangwili, Carmarthen SA31 2AF.

Hospital Medicine (London, England : 1998)
|February 7, 2002
PubMed
Summary

Long-acting beta 2-agonists offer benefits beyond bronchodilation for chronic obstructive pulmonary disease (COPD). This review explores their role as a first-line COPD treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Management of non-thrombolysable acute coronary syndrome (ACS).

Hospital medicine (London, England : 1998)·2005
Same journal

Case report: treatment of faecaloma of the colon.

Hospital medicine (London, England : 1998)·2005
Same journal

Should anaesthetists scrub? The case for and against.

Hospital medicine (London, England : 1998)·2005
Same journal

Angiosarcoma: a difficult diagnosis.

Hospital medicine (London, England : 1998)·2005
Same journal

Pitfalls in recurrent varicose vein surgery.

Hospital medicine (London, England : 1998)·2005
Same journal

Aorto-caval fistula.

Hospital medicine (London, England : 1998)·2005

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • The role of long-acting beta 2-agonists (LABAs) in managing chronic obstructive pulmonary disease (COPD) was previously underestimated.
  • Emerging evidence suggests LABAs provide therapeutic advantages beyond simple bronchodilation.

Purpose of the Study:

  • To review current chronic obstructive pulmonary disease management strategies.
  • To evaluate the position of long-acting beta 2-agonists as a primary therapeutic option for COPD.

Main Methods:

  • Literature review of studies on COPD management.
  • Analysis of clinical evidence supporting the use of long-acting beta 2-agonists.

Main Results:

  • Long-acting beta 2-agonists demonstrate efficacy in COPD management.

Related Experiment Videos

  • Benefits extend beyond bronchodilation, impacting disease progression or symptoms.

    • Conclusions:

    • Long-acting beta 2-agonists are a viable first-line treatment for COPD.
    • Further research may elucidate additional benefits of LABAs in COPD care.